Pathways and targets in hepatocellular carcinoma - PubMed (original) (raw)

Review

. 2012 Oct;12(10):1347-57.

doi: 10.1586/era.12.113.

Affiliations

• PMID: 23176622
• DOI: 10.1586/era.12.113

Review

Pathways and targets in hepatocellular carcinoma

Amanda Psyrri et al. Expert Rev Anticancer Ther. 2012 Oct.

Abstract

The incidence of hepatocellular carcinoma (HCC) has been rising in several western low-incidence areas over the past decade. The purpose of this review was to summarize the current knowledge on the 'state of the art' management of HCC focusing on targeted systemic therapies. The information for this review was compiled by searching the PubMed and MEDLINE databases for articles published until 1 June 2012. Cytotoxic chemotherapy has failed to affect outcome of HCC. Treatment with sorafenib is associated with survival gain in HCC but the responses are not durable. In addition, sorafenib is associated with substantial dermatologic and gastrointestinal toxicity. In this review, the authors summarize molecular targets and signal transduction pathways in HCC and provide an update of published and ongoing studies. Many targeted agents against angiogenesis, Ras/Raf/MAPK, EGF receptor, PI3K/AKT/mTOR, HGF/Met and IGF/IGF receptor are being tested in clinical trials.

PubMed Disclaimer

Similar articles

• Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
  Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ. Cui SX, et al. Oncotarget. 2016 Jun 14;7(24):36767-36782. doi: 10.18632/oncotarget.9168. Oncotarget. 2016. PMID: 27167344 Free PMC article.
• Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
  Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X. Han P, et al. Mol Oncol. 2017 Mar;11(3):320-334. doi: 10.1002/1878-0261.12039. Epub 2017 Feb 17. Mol Oncol. 2017. PMID: 28164434 Free PMC article.
• Targeted therapy of hepatocellular cancer.
  Wysocki PJ. Wysocki PJ. Expert Opin Investig Drugs. 2010 Feb;19(2):265-74. doi: 10.1517/13543780903514110. Expert Opin Investig Drugs. 2010. PMID: 20074016 Review.
• Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
  Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M. Wang Q, et al. J Surg Oncol. 2013 Mar;107(4):422-7. doi: 10.1002/jso.23227. Epub 2012 Jul 25. J Surg Oncol. 2013. PMID: 22833259
• Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
  Weintraub JL, Salem R. Weintraub JL, et al. J Vasc Interv Radiol. 2013 Aug;24(8):1123-34. doi: 10.1016/j.jvir.2013.01.494. Epub 2013 Apr 4. J Vasc Interv Radiol. 2013. PMID: 23562168 Review.

Cited by

• MicroRNA-30a-5p suppresses proliferation, invasion and tumor growth of hepatocellular cancer cells via targeting FOXA1.
  Zhang S, Liu Q, Zhang Q, Liu L. Zhang S, et al. Oncol Lett. 2017 Oct;14(4):5018-5026. doi: 10.3892/ol.2017.6745. Epub 2017 Aug 10. Oncol Lett. 2017. PMID: 29085515 Free PMC article. Retracted.
• Folate-functionalized SMMC-7721 liver cancer cell membrane-cloaked paclitaxel nanocrystals for targeted chemotherapy of hepatoma.
  Shen W, Ge S, Liu X, Yu Q, Jiang X, Wu Q, Tian Y, Gao Y, Liu Y, Wu C. Shen W, et al. Drug Deliv. 2022 Dec;29(1):31-42. doi: 10.1080/10717544.2021.2015481. Drug Deliv. 2022. PMID: 34962215 Free PMC article.
• Insulin-like growth factor-1 prevents miR-122 production in neighbouring cells to curtail its intercellular transfer to ensure proliferation of human hepatoma cells.
  Basu S, Bhattacharyya SN. Basu S, et al. Nucleic Acids Res. 2014 Jun;42(11):7170-85. doi: 10.1093/nar/gku346. Epub 2014 May 9. Nucleic Acids Res. 2014. PMID: 24813441 Free PMC article.
• Systematically Exploring the Antitumor Mechanisms of Core Chinese Herbs on Hepatocellular Carcinoma: A Computational Study.
  Wu Z, He L, Wang L, Peng L. Wu Z, et al. Evid Based Complement Alternat Med. 2020 Sep 15;2020:2396569. doi: 10.1155/2020/2396569. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 33014099 Free PMC article.
• The role of autophagy in hepatocellular carcinoma: friend or foe.
  Liu L, Liao JZ, He XX, Li PY. Liu L, et al. Oncotarget. 2017 Apr 18;8(34):57707-57722. doi: 10.18632/oncotarget.17202. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915706 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal